PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
41.19
Positive OCF/share while Medical - Pharmaceuticals median is negative. Peter Lynch might see a key advantage in a struggling sector.
13.31
Positive FCF/share while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong edge over peers.
67.69%
Capex/OCF ratio of 67.69% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.
0.66
Ratio 0.75–0.9x Medical - Pharmaceuticals median of 0.88. John Neff would push for improved working capital or cost management.
3.16%
OCF-to-sales ratio of 3.16% while Medical - Pharmaceuticals is zero. Walter Schloss might see a modest advantage in actually generating some cash.